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Epidemiological evidence suggests that hypertension may accelerate the onset and progression of Alzheimer’s disease (AD). In this
study, we explored the role of hypertension in the neurodegenerative changes associated with Aβ and tau aggregation. We induced
hypertension in APPswe Tg2576 and P301L-tauTg mouse models. In Tg2576 mice, experimental hypertension was associated with
a signiﬁcant increase of the accumulation of Amyloid-β (Aβ) peptides in brain tissue and a signiﬁcant reduction of Aβ peptides
in serum (P<. 05). These results indicate that hypertension may promote AD-type Aβ neuropathology in Tg2576. In P301L-
tauTg mice we found that the presence of hypertension was signiﬁcantly associated with aggravated motor function assessed by
hindlimb extension test (P = .01). These results suggest that hypertension may play a role in accelerating the progression of motor
dysfunction associated with tau-related alterations. Our studies suggest that the management of blood pressure (BP) may alleviate
AD-type Aβ neuropathology and neurological disorders associated with abnormal tau metabolism.
Copyright © 2009 C. D´ ıaz-Ruiz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
As the population ages, the prevalence of AD dramatically
increases and poses tremendous impact on the provision of
health care and economy, apart from its devastating social
implications. According to Ziegler-Graham et al. [1], if it was
possible to delay the onset of AD by as little as one year,
that would reduce the prevalence of AD by 12million fewer
cases worldwide in 2050. Therefore, it is urgent to identify
eﬀective strategies to prevent or delay the onset or to slow
or reverse AD progression. Identiﬁcation of risk factors is
important for developing preventive strategies. Out of the
many studies to identify potentially preventable risk factors,
the most consistent ﬁnding has been the association of
cognitiveimpairmentwithcardiovasculardiseaseriskfactors
[2].
One of the most common cardiovascular risk factors
is arterial hypertension, and several longitudinal studies
suggest that BP levels are increased decades before the
onset of AD and higher BP seems to accelerate the rate
of cognitive decline in patients with early-onset AD [3,
4]. Furthermore, epidemiological evidence suggests that
hypertension may promote the onset and progression of
Aβ and tau neuropathology. Sparks et al. [5] associated
hypertension with increasing incidence and severity of Aβ
and tau neuropathology in the postmortem brain (e.g.,
parahippocampal gyrus) of nondemented individuals.
Moreover, the Honolulu Heart Program/Honolulu-Asia
aging study reported elevated BP in midlife associated with
greater numbers of neuritic plaques in the neocortex and
hippocampus and greater number of neuroﬁbrillary tangles
(NFTs) in the hippocampus [6], compared to the reference
group.
Furthermore, the early epidemiological studies by Ghika
and Bogousslavsky [7] showed that a transient phase of
high BP occurred before the ﬁrst motor symptoms in
80% of the patients clinically diagnosed with progressive
supranuclear palsy (PSP). More recently, Papapetropoulus
et al. [8] reported that the most common comorbid con-
dition in PSP patients was hypertension, present in 50%2 Cardiovascular Psychiatry and Neurology
of the PSP cases. However, Colosimo et al. [9] showed
that prevalence of hypertension in pathologically proven
PSP patients was no higher than in controls. Colosimo
et al. [9] suggested that the apparent association between
hypertension and PSP reported by Ghika might be due to the
inclusion of multiinfarct/multilacunar states masquerading
clinically as PSP. Because an association between brain
vascular lesions, hypertension, and PSP is plausible, Sibon
et al. [10] asserted that determining the exact frequency of
hypertension in PSP patients will require careful, unbiased
clinical diagnoses to distinguish “mixed” from “pure” PSP
cases.
The controversy of the epidemiological data shows the
need for clariﬁcation in order to properly address the
implications of managing BP as prevention strategy of AD.
In an eﬀort to clarify this controversy, we experimentally
explored the potential causal relationship between high
BP and the onset and/or progression of AD-type Aβ
neuropathology and tau-mediated motor dysfunction. We
examined the hypothesis that induction of hypertension in
Tg2576 and P301L tau Tg mouse models would inﬂuence
the onset and/or progression of AD-type Aβ neuropathology
and tau-mediated phenotypes, respectively.
2.MaterialsandMethods
2.1. Mouse Models
2.1.1. Tg2576 Mouse Model of Aβ Neuropathology. We used
female Tg2576 AD transgenic mice [11] obtained from
Taconic Farms. Tg2576 mice express the human 695-amino
acid isoform of the Amyloid precursor protein (APP) con-
taining the Swedish double mutation (APPSwe) [(APP695)
Lys670→Asn, Met671→Leu] driven by a hamster prior
promoter, which leads to extracellular accumulation of both
Aβ (1-40) and Aβ (1-42/43) peptides, as well as soluble
high-molecular-weight Aβ oligomers and amyloid plaque
deposition in cortical and limbic structures.
2.1.2. P301L-Tau Tg Mouse Model of Tau-Neuropathology.
We used hemizygote female JNPL3 mice [12] obtained from
Taconic Farms. We refer to these mice as P301L-tau Tg
mouse model of tauopathy. The P301L-tau Tg mouse model
expresses human tau with the most common FTDP-17
P301L mutation under the prion protein promoter. It is one
of the best characterized mouse models of tauopathy and it is
wellacceptedandconsideredtobeanexcellentinvivomodel
for studying consequences of tangle development.
All animal studies were approved by the Institutional
Animal Care and Use Committee of Mount Sinai School of
Medicine.
2.2. Induction of Hypertension. Angiotensin II infusion
method and Deoxycorticosterone acetate (DOCA)-salt
method were used to induce essential hypertension in
Tg2576 and P301L-tau Tg mice, respectively. These two
methods model the two mechanisms underlying most of the
cases of essential hypertension in humans.
2.2.1. Induction of Chronic Hypertension Using Angiotensin
II Infusion Method. We induced chronic hypertension in
Tg2576 mice by infusing AngiotensinII.
This experimental model system induces a fast and
consistent elevation of the BP, appropriate for a short-
durationtreatment.Inourstudies,treatmentlastedfrom5to
7months of age, corresponding to the critical period during
which an exponential accumulation of Aβ peptides occurs in
Tg2576 mice.
Female Tg2576 mice were treated with Angiotensin II
(Sigma 1.1mg/Kg/day in 0.9% NaCl), infused for 8weeks
by means of 28-day micro-osmotic pumps (Alzet, Durect
Corporation, Calif, USA, model 1004) implanted subcuta-
neously at the back of the neck. In control studies, age-
strain- gender- matched Tg2576 mice were treated with
0.9% NaCl also infused by means of micro-osmotic pumps.
The pumps were replaced once, after the ﬁrst month of
treatment.
Follow-up assessment included measurements of BP and
body weight once every two weeks.
2.2.2. Induction of Chronic Hypertension Using the DOCA-
Salt Paradigm. We induced chronic hypertension in WT and
P301L-tau Tg mice using the DOCA-salt method.
This experimental model system progressively induces
hypertension and was appropriate for a long-duration treat-
ment, given the fact that symptoms of motor dysfunction
slowly develop in the P301L-tau Tg mice. Mice were
chronically treated with DOCA-salt for 8months, starting at
5.5monthsofage,3monthsbeforetheﬁrstmotorsymptoms
start in this mouse model, and ending at 13.5months of age.
Brieﬂy, mice assigned to the hypertensive group under-
went right unilateral nephrectomy at 20weeks of age.
A f t e r2 w e e k so fr e c o v e r y ,9 0 - d a y - r e l e a s eD O C Ap e l -
lets (50mg/pellet, Innovative Research of America) were
implantedsubcutaneouslybyincisionatthebackoftheneck.
DOCA pellets were replaced every 3months. Starting with
the initial DOCA pellet implantation, mice in the hyperten-
sive group received additional dietary salt chronically until
the end of the study by incorporation of 1% NaCl into the
drinking water.
Age-, strain-, and gender-matched P301L-tau Tg mice
assigned to the control group also underwent the same
procedure but were implanted subcutaneously with 90-day-
release placebo pellets (50mg/pellet Innovative Research
of America). This treatment does not lead to detectable
modiﬁcations in BP.
Follow-up assessment included measurements of BP and
body weight once every two weeks.
2.3. Blood Pressure Measurements. BP measurements were
conducted using a BP analysis system designed for small
rodents according to manufacture’s instruction (Hatteras
Instruments, NC, USA). Speciﬁcally, mice were temporarily
immobilized in a restraining chamber, the tail was inserted
through the tail cuﬀ and laid down into the tail slot, secured
with a piece of tape. Every mouse underwent 5preliminary
cycles for which data was not recorded. The followingCardiovascular Psychiatry and Neurology 3
10measurements of systolic, diastolic, and mean arterial
pressure (MAP) were recorded and the mean values were
used for each animal.
2.4. Behavioral Tests
2.4.1. Assessment of Cognitive Function by Morris Water
Maze Test. The Tg2576 mouse model is well known to
develop progressive cognitive deterioration associated with
accumulationofAβpeptidesinthebrainwithincreasingage,
starting at 6months of age [11].
Therefore, spatial learning memory was assessed by the
Morris water maze (MWM) behavioral test, as described
previously [13] after two months of hypertension. In this
assay, mice were tested in a 1.25m circular pool ﬁlled with
water mixed with nontoxic white paint (Dick Blick Art
Materials). Mice were trained to mount a hidden/submerged
(1.5cm below water surface) escape platform (14 ×14cm) in
a restricted region of the pool. Spatial memory was assessed
by recording the latency time for the animal to escape from
the water onto a submerged escape platform as a function
of the number of learning trials during the learning phase.
The water maze activity was monitored with the San Diego
Instrument Poly-Track video tracking system.
2.4.2. Motor Function Assessment of P301L-Tau Tg Mice.
P301L-tau Tg mice are known to develop progressive motor
impairment [14]. We assessed the motor function of these
mice by the hindlimb extension assay. For that purpose, we
established a scale from 1 to 4, which allowed us to clearly
distinguish 4 diﬀerent phenotypes (Figure 3(a)).
P301L-tau Tg mice were tested in the presence and
absenceofexperimentallyinducedhypertension.Tomonitor
hindlimb extension, mice were elevated by the tail by two
diﬀerent investigators who were blind to the treatment. The
unimpaired animals, which generally place their legs in a
wide “V” away from their bodies, were scored 4 and were
identiﬁed as “normal phenotype.” We scored 3 when the
mice were not able to completely separate the legs from the
body, sometimes displaying a trembling leg, but with no
dystonicsymptoms.Thisgroupwasconsideredtohave“mild
phenotype.” When dystonic symptoms were present, but the
mice still had the ability to move their legs, we scored 2 and
they were assigned the “moderate phenotype.” Finally, we
scored 1 when the mice showed “severe phenotype”, with
very dystonic hindlimbs, and were unable to perform any
leg extension or movement when elevated by the tail. Each
test score was the average of two trials of 3 and 5seconds,
respectively.Werepeatedthetesttwicethesamedayonehour
apart, twice more the following day, and once one week later.
The ﬁnal score for each mouse was the average of the 5tests.
We monitored the hindlimb extension at 11 and 14months
of age (after 5 and 8months of treatment, resp.).
2.5. Neuropathological Analysis
2.5.1. Assessment of AD-Type Amyloid Neuropathology in
Tg2576 Mice. For quantitative assessment of brain Aβ
peptides, frozen pulverized tissue was homogenized in 5.0M
guanidine buﬀer, diluted (1 : 10) in phosphate-buﬀered
saline containing 0.05% (v/v) Tween-20 and 1mM Pefabloc
protease inhibitors (Roche Biochemicals, Indianapolis, Ind,
USA) and centrifuged for 20 minutes at 4◦C. Total Aβ1-40 or
Aβ1-42inthesupernatantwasquantiﬁedbysandwichELISA
(BioSource, Camarillo, Calif, USA), as previously reported
[15].
2.5.2. Assessment of Tau Neuropathology in P301L-Tau Tg
Mice. Abnormal accumulation of pathological tau species
(64,140,and170KDa)inthespinalcordoftheP301L-tauTg
mice has been associated with the motor deﬁcits developed
in this mouse model [14, 16]. We followed Berger et al.
procedures [16] to evaluate the presence of tau species in
the spinal cords of both control and hypertensive P301L-
tau Tg mice by Western blot. Brieﬂy, spinal cords were
homogenized in 10 × volume of the following mM: 50mM
Tris-HCl, pH 8.0, 274mM NaCl, 5mM KCl, 2mM EGTA,
2mM EDTA, protease inhibitor cocktail (Sigma, St. Louis,
Mo, USA), phosphatase inhibitor cocktail I and II (Sigma).
The homogenate was sonicated and spun for 15minutes at
13000 ×g,andthesupernatantwasanalyzedbyWesternblot
(NFTs and cell debris were removed in the pellet). Proteins
were separated on 10% SDS-PAGE Tris-glycine gels (Invitro-
gen) and wet transferred to nitrocellulose membranes. The
membraneswereblockedin5%milkinPBST,andincubated
with primary antibodies overnight. The following antibodies
were used: PHF1 (anti-phospho-tau epitope S396-S404, 1 :
2000, generous gift from P. Davis), AT8 (anti-phospho-
tau epitope S202-S205, 1 : 1000; Pierce, Rockford, Ill,
USA), and anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (1 : 10000, Chemicon International). Secondary
antibodies (Santa Cruz) were used at 1 : 20000 in 2%
milk-PBST. Labelling was visualized using Western lightning
Chemiluminescence reagent (PerkinElmer, Wellesley, Mass,
USA). For densitometric analysis, ImageJ program was used.
The intensity of the protein band of interest was divided
by the intensity of the band representing a loading control
GAPDH to calculate the relative amount.
2.6. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n
± standard error of the mean (SEM). Diﬀerences between
means were analyzed using two-tailed Student’s t test versus
normotensive-control mice. In all analyses, the null hypoth-
esis was rejected at the 0.05 level. All statistical analyses were
performed using the Prism Stat program (GraphPad Prism 4
Software, Inc., San Diego Calif, USA).
3. Results and Discussion
3.1. Experimental Hypertension Models Signiﬁcantly Elevated
Blood Pressure in Tg 2576 and P301L-Tau Tg Mice. Experi-
mental hypertension had no aversive eﬀect on body weight
of mice versus normotensive control mice (Figures 1(a) and
1(c)).
Angiotensin II treatment signiﬁcantly increased BP of
Tg2576 mice by 20% (P = .02), as shown by the systolic4 Cardiovascular Psychiatry and Neurology
(28.4% increase), diastolic (16.6% increase) and MAP
(20.8% increase) values (Figure 1(b)). Elevation of MAP was
reached after two weeks of treatment and was consistently
maintained over the two-month duration of the experiment.
DOCA-salt method of hypertension induction was not used
in this speciﬁc study because DOCA-salt method increases
the liquid uptake and urine secretion which will disrupt the
homeostasis balance of amyloid peptides between blood and
brain.
Also, DOCA-salt method progressively induced chronic
hypertension in the P301L-tau Tg mice compared to the
placebo-salt group (control group) as indicated by systolic,
diastolic and MAP values (Figure 1(d)).
After one month of treatment, the MAP of the DOCA-
salt treated mice (hypertensive group) was already signiﬁ-
cantly elevated, by 10% (P = .01 data not shown). From 3
to 5months of DOCA-salt treatment, MAP values reached
a 30% increase versus placebo-salt treatment (P<. 005,
Figure 1(d)). By the end of the study, after 8months of
DOCA-salt induced hypertension, the MAP reached 40%
higher values than controls (P<. 0001, Figure 1(d)).
The DOCA-salt method induced elevation of BP in WT
mice in a similar pattern as in P301L-tau Tg mice.
3.2. Hypertension May Have a Causative Eﬀect in Promoting
Aβ Neuropathology of AD-Type. ELISA analysis showed that
experimental hypertension signiﬁcantly increased by 57%,
the accumulation of Aβ1-42 peptide (P = .01) in brain tissue
relative to age-, strain-, and gender-matched control Tg2576
mice (Figure 2(c)). Accumulation of Aβ1-40 in brain tissue
was also increased, by 51% (P = .02), compared to control
animals (Figure 2(c)). Increase of Aβ peptides in the brain
was accompanied by a signiﬁcant 30% reduction of both
Aβ1-42 and Aβ1-40 peptides in the serum of these animals
(P = .02, Figure 2(d)).
Our ﬁnding of aggravated Aβ load in brain tissue of
hypertensive Tg2576 mice experimentally supports previous
epidemiological Honolulu Heart Program/Honolulu-Asia
aging study [6], which had demonstrated an association
between midlife elevation of BP and Aβ deposition in the
neocortex and hippocampus of AD patients.
We hypothesized that accumulation of Aβ peptides in
brain of hypertensive mice, concomitant to the decrease of
Aβ peptides in serum of these animals could be due to the
dysregulation of Aβ traﬃcking in and out of the brain. Our
hypothesis is supported by the data reported by Gentile et al.




increased blood-brain barrier (BBB) permeability of blood-
born substances in the cortex and hippocampus, suggesting
a bloodstream origin of the brain amyloid deposits, rather
than a neuronal source. These studies correlate well with our
ﬁnding of increased levels of Aβ peptides in the brain and
decreased levels in serum. However, in addition to changes
in BBB permeability, we cannot rule out the possibility of
dysregulation of Aβ transporters aﬀecting the traﬃcking
of Aβ peptides from the brain to the serum, decreasing
the clearance of Aβ peptides from the brain of Tg2576
mice.
Consistent with previous results [11], control Tg2576
mice at 7 months of age showed impaired acquisition of
spatial learning, as assessed by MWM test. The mice failed
to learn to use the available visual cues to help locate a
submerged escape platform, as indicated by the lack of
signiﬁcant improvements in the escape latency across con-
secutive learning sessions (Figures 2(a) and 2(b)). Similarly,
hypertensive strain-, age-, and gender-matched Tg2576 mice
were also unable to locate the escape platform (Figures 2(a)
and 2(b)). We did not observe a signiﬁcant diﬀerence in the
spatial learning ability by the MWM test between the two
groups.
Hypertension induced by angiotensin II infusion for
8weeks in Tg2576 mice signiﬁcantly increased the content
of total Aβ peptides in the brain compared to normotensive
Tg2576 control mice. However, we failed to identify any
signiﬁcant alteration in spatial memory function. It is pos-
sible that hypertension induced by angiotensin II increased
total Aβ content without signiﬁcant impact on the amount
of oligomeric Aβ, which is largely responsible for cognitive
deterioration in the mouse model of AD. It is also possible
that the degree of hypertension imposed to the mice is quite
mild (elevation of BP by 20%). More severe hypertension
condition might be needed to cause worse cognitive function
in this mouse model.
3.3. Chronic Hypertension May Have a Role in Aggravat-
ing the Progression of Tau-Mediated Motor Impairment. As
mentioned before, the P301L tau Tg mice, so it reads
P301L Tg mice progressively develops motor impairment
over an extended period of time. Hypertension induction
by Angiotensin II infusion through micro-osmotic pump
requires surgical implants every 28days. Each surgical
maneuver puts animals under stress and sometimes mortal-
ity. Therefore, we used the DOCA-salt method which only
needed replacement of the implants three times over the
8months of treatment.
The control P301L tau Tg mice assessed at 11months of
age by hindlimb extension test showed “normal phenotype,”
according to the score scale that we deﬁned to distinguish the
diﬀerent phases of the motor impairment mediated by tau
(Figure 3(a)). Thus, the average hindlimb extension score of
the control group was 3.49 ± 0.17 (Figure 3(b)).
At the same age, after 5months of hypertension induc-
tion P301L tau Tg mice displayed “mild phenotype,” as
indicated by an average score for the hindlimb extension test
of 3.06 ± 0.25 (Figure 3(b)).
Statistical analysis of the data using the two-tailed
Student’s t test showed no signiﬁcant diﬀerences between
the control and the hypertensive P301L-tau Tg groups on
motor function assessed by the hindlimb extension test at
11months of age. These results indicate that 5months of
experimental hypertension did not signiﬁcantly aﬀect the
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Figure 1:ExperimentallyinducedhypertensionsigniﬁcantlyelevatedthebloodpressureofTg2576andP301L-tauTgmice.(a),(c)Experimental
hypertension had no aversive eﬀe c to nb o d yw e i g h to fm i c eversus normotensive control group. (b), (d) Experimental hypertension
progressively elevated BP as shown by systolic, diastolic and mean arterial pressure (MAP). Values represent mean ± SEM values. (a),
(b) n = 6 mice per group. (c), (d) n = 10 mice per group. Diﬀerences between means were analyzed using two-tailed Student’s t test versus
control normotensive mice, ∗P<. 05 , ∗∗∗P<. 0001 by two-tailed Student’s t test analysis.
At 14months of age the control P301L-tau Tg mice
had “mild phenotype,” as shown by an average score in the
hindlimb extension test of 3.24 ± 0.24.
Interestingly, at this age, after 8months of hypertension,
the average hindlimb extension score of the hypertensive
grouphaddroppeddownto2.22 ± 0.29, identiﬁed as “mod-
eratephenotype.”Mostimportantly,thehypertensiveP301L-
tau Tg group showed signiﬁcantly worsened phenotype,
by 30%, compared to age-, strain-, and gender-matched
normotensive control animals at this stage of the study
(Figure 3(b), P = .01).
Indeed, compared to control P301L-tau Tg mice, hyper-
tensive P301L-tau Tg mice showed signiﬁcantly greater
leg weakness, dystonic posturing and hindlimbs with clear
tendency to clasp. Consistent with the observation that
hypertension is associated with more severe motor impair-
ment in P301L-tau Tg mice, motor impaired hypertensive
mice were also characterized by poor grooming (urine
scalding/oily fur, not shown). We only occasionally observed
dystonic hindlimbs in the age-, strain-, and gender-matched
control mice. None of the control P301L-tau Tg mice had
problems with grooming.
At the end of the study, at 14months of age, motor
function scores of P301L-tau Tg mice showed a signiﬁcant
negative correlation between systolic BP (P = .044,r =
























































































































































































































Figure 2: Hypertension promoted AD-type Aβ neuropathology in Tg2576 brains. (a), (b) Assessment of spatial memory in hypertensive Tg
2576 mice versus control normotensive mice by MWM test showed no eﬀect of hypertension in the inability to learn of Tg 2576. Latency
s c o r er e p r e s e n t st i m et a k e nt oe s c a p et ot h ep l a t f o r mf r o mt h ew a t e r .( a ) Visible platform acquisition. (b) Hidden platform acquisition. (c)
A 2-month period of hypertension signiﬁcantly increased the accumulation of Aβ1-40 and Aβ1-42 peptides by 57 and 51%, respectively, in
brain tissue of Tg2576 mice. (d) This increase of Ab peptides in the brain was accompanied by a signiﬁcant 30% reduction of both Aβ1-42
and Aβ1-40 peptides in the serum of Tg2576 mice. Values represent mean ± SEM values, n = 6m i c ep e rg r o u p .D i ﬀerences between means
were analyzed using two-tailed Student’s test versus control mice, ∗P<. 05.
R2 = 0.2), suggesting that hypertension may be promoting
clinical motor impairment.
The motor disturbances developed by P301L-tau Tg
mice have been correlated with the presence of abnormally
hyperphosphorylated tau species in the spinal cord of these
mice [14, 16]. Therefore, we proceeded to evaluate whether
hypertension inﬂuenced tau neuropathology present in
spinal cords.
Western blot analysis of spinal cords from WT mice
showed normal 50KDa tau species (Figure 3(c)). Spinal
cords of control P301L-tau Tg mice showed abnormal
accumulation of 64, 140, and 170KDa pathological tau
species (Figure 3(c); 14, 16). Quantitative analyses of patho-
logical tau species found in control P301L-tau Tg samples
showed a negative correlation with hindlimb extension
scores (P = .01,r = 0.7,R2 = 0.5). Our data sup-
port the hypothesis that motor impairment developed by
P301L-tau Tg mice may be mediated by the abnormal tau
species.
However, densitometric analysis of Western blot tau
species (50, 64, 140, and 170KDa) present in spinal cords











































































































Figure 3: Chronic hypertension aggravated motor deﬁcits assessed by hindlimb extension test in P301L-tau Tg mice. (a) Score scale used to
assess motor function of the P301L-tau Tg mice by the hindlimb extension test. (b) Motor function assessed by hindlimb extension test
of P301L-tau Tg mice was not aﬀected after inducing hypertension for 5 months (11 months of age), but was signiﬁcantly aggravated, by
30%, after inducing hypertension for 8 months (14 months of age). Score values represent mean ± SEM of 5 tests. Also
∗P <. 01, by
two-tailed Student’s t test analysis. (c), (d) Hypertension did not signiﬁcantly alter tau neuropathology in spinal cords of P301L-tau Tg. (c)
Representative Western blot for tau species of WT and P301L-tau Tg (control and hypertensive) spinal cord samples. GAPDH was used as
a loading control. (d) Densitometric quantiﬁcation of the 170 KDa tau species levels in spinal cord samples. Values represent mean ± SEM
values. n = 10 mice per group. Diﬀerences between means were analyzed using two-tailed Student’s t test versus control mice.
detect a signiﬁcant increase in the immunoreactivity of
any of the tau species (Figure 3(d)), as shown for the
representative 170KDa tau species. These results indicate
that the aggravated motor disturbances associated with
induced chronic hypertension were not mediated by tau
neuropathology.
Alternatively, we think that responsible factors could be
vascular and/or white matter lesions [3, 18, 19], occurring8 Cardiovascular Psychiatry and Neurology
with long history of hypertension. Future studies in our
lab will be addressing the eﬀect of hypertension in these
lesions and whether or not they inﬂuence the progression
of the motor deﬁcits in a tau-independent but convergent
manner.
On the other hand, it is also very likely that the motor
function of the P301L-tau Tg mice assessed by hindlimb
extension only becomes signiﬁcantly sensitive to hyperten-
sion when the clinical progression of the disease reaches a
certain threshold. In agreement with the possible existence
of a “critical point” in the development of behavioral deﬁcits
by P301L-tau Tg mice, Morgan et al. [20] have recently
reported that hindlimb motor paralysis secondary to tau
aggregate formation did not exhibit antecedent deﬁcits in
motor behavior prior to the onset of paralysis.
While the mechanistic basis for the aggravated motor
phenotype associated with chronic hypertension in P301L-
tau Tg mice is not clear, our observation suggests that it
maybenecessarytoreexamineepidemiologicaldatashowing
that hypertension was present in a high percentage of PSP
patients [7, 8] to separately explore “mixed cases” with
vascular lesions from “pure PSP cases,” for a better under-
standing of the actual association between hypertension and
movement disorders mediated by abnormal metabolism of
tau.
Furthermore, the interaction between Aβ and tau neu-
ropathology may be necessary to modify the “critical point”
in an additive manner or in an order of magnitude greater
than in a simple additive eﬀect. Therefore, further studies in
double transgenic mouse models showing both Aβ and tau
neuropathologies are required to fully address the question
on the role of hypertension in dementia of AD-type.
Taken together, our studies suggest that BP management
may have a beneﬁcial eﬀect delaying and/or attenuating Aβ
neuropathology present in AD patients, and may also atten-
uate the increasingly severe progression of the movement
disorders present in patients with tauopathies.
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